DCTD Programs
FOLLOW DCTDDCTD Staff Present at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
DCTD staff are presenting research at the 28th
EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” 
(November 29-December 2, 2016; Munich, Germany). Posters on a variety of topics and an oral presentation on
assays in early stage clinical trials are being highlighted. Also, DCTD’s Director, James H. Doroshow, MD,
is co-chairing a proffered paper session. The symposium is co-hosted by the European Organisation for Research
and Treatment of Cancer (EORTC), NCI, and the American Association for Cancer Research (AACR). These meetings provide
a venue for the international cancer research community to discuss findings from preclinical and phase 1 studies.
| Presentation type | Authors | Title |
|---|---|---|
| Wednesday, November 30, 2016 | ||
|
Poster Session: Clinical Trial Methodology Poster 004 |
S.X. Yang, D. Nguyen, M. Hollingshead, L. Rubinstein, J.H. Doroshow |
DCMT3B expression patterns in human lymphomas and xenograft tumors |
Poster Session: Clinical Trial Methodology Poster 011 |
K. Ferry-Galow, H. Makhlouf, R. Kinders, A. Chen, J.H. Doroshow, R. Parchment |
Suitability of post-diagnostic core needle tumor biopsies for correlative studies of molecular drug action pharmacodynamics) |
Poster Session: Drug Screening Poster 058 |
B. Teicher, M. Kunkel, D. Evans, R. Delosh, J. Laudeman, O. Chad, R. Reinhart, S. Michael, S. Thomas, G. Kaur, A. Monks, J. Morris |
Adult and pediatric sarcoma cell line screen findings in Notch, DNA repair and cell cycle gene and miR expression and compound response |
Poster Session: Epigenetic modulators Poster 095 |
G. O’Sullivan Coyne, A.P. Chen, S. Kummar, R.S. Meehan, J. Collins, J. Zlott, K. Kelly, H.J. Lenz, E.M. Newman, R. Morgan, L. Juwara, J. Eiseman, J.H. Beumer, J. Tomaszewski, J. Doroshow |
Phase I trial of oral 5-fluoro-2’-deoxycytidine with oral tetrahydrouridine in patients with advanced solid tumors |
Plenary Session 2 |
Co-chair: J.H. Doroshow |
Proffered Paper Session |
| Thursday, December 1, 2016 | ||
Poster Session: New Therapies with Pleiotropic Activity Poster 145 |
R.S. Meehan, S. Kummar, G. O’Sullivan Coyne, J. Zlott, Y. Horneffer, L. Juwara, H. Streicher, E. Sharon, P. Harris, J.H. Doroshow, A. Chen |
Phase 1 study of ganetespib and ziv-aflibercept in patients with advanced gastrointestinal carcinomas, non-squamous non-small cell lung carcinomas, urothelial carcinomas, and sarcomas |
Poster Session: Molecular targeted agents II Poster 097 |
A. Chen, B. Conley, S. Hamilton, M. Williams, P. O’Dwyer, C. Arteaga, R. Gray, L. McShane, S. Li, L. Rubinstein, D. Patton, K. Sazali, J. Zwiebel, E. Mitchell, M.L. Smith, D. Dragaud, R. Little, R. Comis, J. Abrams, K. Flaherty. |
NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: A novel public-private partnership |
Regulatory Session: The Regulatory Field for Biomarkers and Diagnostics Oral Presentation |
M. Williams |
Selecting the best assay for early stage clinical trials |